The discovery of this novel TRH receptor subtype (which is pharmacologically different from the one already described) will help to draw attention to the use of TRH analogs to treat the symptoms of ALS and other neurodegenerative diseases. This evidence concerns the gene TRH and neurodegenerative disease.